[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
News From the Food and Drug Administration
March 6, 2002

Drug for Pediatric Liver Disease

Author Affiliations

Not Available

Not Available

JAMA. 2002;287(9):1103. doi:10.1001/jama.287.9.1103-JFD20003-3-1

The FDA has approved nitisinone capsules (Orfadin, Swedish Orphan International AB, Stockholm, Sweden) for use as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1).

Nitisinone was studied in more than 200 patients whose median age was 9 months when therapy started. The drug's effectiveness was inferred by its effect on reduction of concentration of succinylacetone in plasma and urine to a level below the reference limit, and by normalization of erythrocyte porphobilinogen synthase activity. Resulting improvements in these indices were statistically significant (P<.001).